Scienza e Tecnologia
Cristal Therapeutics announces a publication in 'Chemical Science' on CliCr® technology platform, comprising a new class of superior copper free click reagents for conjugation of small molecules, biologics, nanoparticles and other moieties
MAASTRICHT, The Netherlands , Sept. 29, 2020 /PRNewswire/ -- Cristal Therapeutics, a Dutch phase 2 clinical-stage pharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases with high unmet patient need, announces publication in , the flagship journal of the Royal Society of Chemistry, of an article on the development of TMTHSI as part of the CliCr platform providing fast and versatile conjugation tools.
For the optimal performance of CriPec nanomedicines, it is essential to be able to attach a broad range of small molecule active agents and large molecular entities, biologics, to CriPec nanoparticles.
The published research reports the development of a convenient and versatile fast-reacting molecular entity for gluing very different compounds in a strain-promoted azide-alkyne cycloaddition click reaction to the nanoparticles, as well as a collection of linkers to attach the widely varying active small molecules and biologics. Next to the already demonstrated examples, many additional applications are foreseen such as the construction of antibody drug conjugates in aqueous environments with faster kinetics that is essential for these delicate constructs.
CliCr is also used to generate virus mimicking nanoparticles. CriVac is a unique antigen carrier platform based on CriPec nanoparticles that, in contrast to viral vectors, do not convey a bystander immune response. CriPec particles' size resemble a virus and the desired numbers of antigen displayed on its surface are controlled via CliCr . CriVac mimics features of a live virus in a tailored manner to induce immunity safely, efficiently and solely to the displayed antigen, offering a prophylactic vaccination strategy which will be readily adaptable to different pathogenic treats.
The very attractive functionalisation possibilities, combined with its versatility, great reactivity and small size offer multiple opportunities for CliCr reagents to become the new standard for non-copper catalyzed click reactions in a multitude of applications.
In case you are interested to learn about the CliCr platform, please reach out to www.clicr.eu or talk to us at the following virtual conferences
J. Weterings et al. ,
https://pubs.rsc.org/en/content/articlehtml/2020/sc/d0sc03477k
Cristal Therapeutics is a phase 2 clinical-stage pharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases with high unmet patient need and considerable commercial potential. The Company's product candidates are based on its proprietary CriPec polymeric nanoparticle technology platform, which enables the design of customized nanomedicines with superior therapeutic profiles. CriPec -based products have the potential to provide enhanced efficacy and reduced side effect profiles, thus offering improved disease treatment.
Find out more: www.cristaltherapeutics.com
Jeroen van Egmond
Consultant Business Development
T: +31 6 272 048 89
E: jeroen.vanegmond@cristaltherapeutics.com
Photo: https://mma.prnewswire.com/media/1283087/Cristal_Therapeutics_Infographic.jpg